

David L. Bahnsen
Frequent guest on CNBC, Bloomberg, and Fox Business. Host of The Dividend Cafe and author of multiple books.
Top 3 podcasts with David L. Bahnsen
Ranked by the Snipd community

15 snips
Apr 8, 2025 • 1h 17min
431: David Bahnsen—Poor Smart and Desperate
David Bahnsen, founder and chief investment officer of The Bahnsen Group, discusses the essential role of work in life beyond just financial gain, diving into how capitalism intertwines with Christian values. He critiques universal basic income as dehumanizing and promotes meaningful work over mere leisure. The conversation also reveals insights on economic mobility, creativity in the workplace, and the importance of self-motivation. Bahnsen’s personal journey highlights the balance of initiative and desperation in shaping fulfilling career paths.

Mar 24, 2025 • 39min
3.24.25 Legal Docket on prisoner grievance rights, David Bahnsen traces the origin of Moneybeat, and History Book on the life of Jonathan Edwards
David Bahnsen, a financial analyst known for integrating Christian perspectives into market economics, discusses the Supreme Court's rulings on prisoner grievance rights and their impact on justice. He reflects on the severe economic downturn during the COVID-19 pandemic, offering an optimistic view on recovery and the importance of faith in navigating economic challenges. Additionally, the life of Jonathan Edwards is explored, underscoring his influence during the Great Awakening and the enduring significance of faith through trials.

Mar 20, 2025 • 1h 12min
Inflation, the Economy, and Drugs
David Bahnsen, a managing partner at the Bahnsen Group, and Tevi Troy, an author focusing on Big Pharma, dive deep into today's economic landscape. They tackle the Federal Reserve’s inflation talk and the political ramifications of tariffs on housing and market growth. The duo also discusses the pharmaceutical industry's innovations amidst public scrutiny over drug pricing. Additionally, they consider the impact of direct-to-consumer advertising and the potential of AI in drug development, highlighting the balancing act between regulation and innovation.